Prothena Q1 net loss widens to $46.9M; pipeline progress with PRX012, PRX005 data

PROTHENA CORP PUBLIC LTD CO

2023-Q1 EPS reported -$0.89 revenue$2,169,000

Net loss of $46.9M ($0.89 per share) vs $36.3M ($0.78) in Q1 2022; revenue $2.2M from BMS collaboration.
Cash position $688.4M; FY 2023 guidance: net cash used $213-229M, year-end cash ~$512M.
PRX012 preclinical data at AD/PD showed 20-fold higher affinity vs lecanemab; PRX005 Phase 1 SAD met safety objective.
Key milestones: PRX012 topline data year-end 2023; birtamimab Phase 3 AFFIRM-AL topline in 2024.
R&D expenses rose to $44.8M from $27.3M driven by clinical trial costs.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PROTHENA CORP PUBLIC LTD CO reported first quarter of 2023 results: net income $46.9 million.

Period: first quarter of 2023
Net income: $46.9 million
Result: reported results

Exact text from the filing

For the first quarter of 2023, Prothena reported net loss of $46.9 million

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

PROTHENA CORP PUBLIC LTD CO filing history →

Source: SEC EDGAR

accession 0001559053-23-000014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.